Comparative Pharmacology
Head-to-head clinical analysis: FLOWTUSS versus GUAIFENESIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOWTUSS versus GUAIFENESIN.
FLOWTUSS vs GUAIFENESIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FLOWTUSS (guaifenesin) is an expectorant that increases respiratory tract fluid secretions, reducing mucus viscosity and facilitating clearance.
Guaifenesin is an expectorant that increases respiratory tract fluid secretion and reduces mucus viscosity, facilitating expectoration.
10 mg orally every 4-6 hours as needed for cough; maximum 60 mg/day.
Oral: 200-400 mg every 4 hours as needed, not to exceed 2400 mg/day.
None Documented
None Documented
Terminal elimination half-life is 4–6 hours in adults with normal renal function; prolonged to 8–12 hours in moderate renal impairment (CrCl 30–50 mL/min).
Terminal elimination half-life: 3-5 hours; clinical context: requires dosing every 4-6 hours for sustained mucolytic effect
Renal elimination of unchanged drug accounts for 60–70%; hepatic metabolism (30–40%) with fecal excretion of metabolites via bile (20–25%) and urine (10–15%).
Renal: ~95% (primarily as unchanged drug and glucuronide conjugate); biliary/fecal: minimal (<5%)
Category C
Category C
Expectorant
Expectorant